Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 9/20 | 0.74 |
| ▸ | ADRA1D | P25100 | 8/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 8/20 | 0.74 |
| ▸ | ADRA1B | P35368 | 8/20 | 0.74 |
| ▸ | DRD4 | P21917 | 5/20 | 0.67 |
| ▸ | DRD2 | P14416 | 4/20 | 0.67 |
| ▸ | DRD3 | P35462 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL2906266 | 0.98 | HTR1A (0.72) | HTR1AADRA1DADRA1AADRA1BDRD4 | |
| Bromide SCHEMBL9548125 | 0.98 | HTR1A (0.72) | HTR1AADRA1DADRA1AADRA1BDRD4 | |
| Hydrochloric Acid SCHEMBL8159235 | 0.98 | HTR1A (0.72) | HTR1AADRA1DADRA1AADRA1BDRD4 | |
| SCHEMBL11701339 | 0.91 | DRD4 (0.77) | HTR1AADRA1DADRA1AADRA1BDRD4 | |
| SCHEMBL9273085 | 0.88 | HTR1A (0.64) | HTR1AADRA1DADRA1AADRA1BDRD4 | |
| SCHEMBL11711163 | 0.88 | HTR1A (0.58) | HTR1AADRA1DADRA1AADRA1BDRD4 | |
| SCHEMBL7394364 | 0.87 | HTR1A (0.75) | HTR1AADRA1DADRA1AADRA1BDRD4 | |
| SCHEMBL11148020 | 0.85 | HTR1A (0.73) | HTR1AADRA1DADRA1AADRA1BDRD4 | |
| SCHEMBL11712614 | 0.84 | HTR1A (0.58) | HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL6567503 | 0.84 | BCHE (0.62) | HTR1AADRA1DADRA1AADRA1BDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756057-B1 | PROCESS FOR THE PREPARATION OF CARVEDILOL | CIPLA LTD (IN) | 2010-08-04 | — | — | EP | claimed |
| US-7705163-B2 | Process for the preparation of carvedilol | CIPLA LIMITED (IN) | 2010-04-27 | — | — | US | claimed |
| US-7482471-B2 | Process for preparation of 1-[9H-carbazol-4-yloxy]-3-[{2-(2-(-methoxy)phenoxy)-ethyl}-amino]-propan-2-ol | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2009-01-27 | — | — | US | claimed |
| US-20080234492-A1 | Process for the Preparation of Carvedilol | CIPLA LIMITED (IN) | 2008-09-25 | — | — | US | claimed |
| EP-1756057-A1 | PROCESS FOR THE PREPARATION OF CARVEDILOL | Cipla Ltd. (IN) | 2007-02-28 | — | — | EP | claimed |
| US-20060270858-A1 | A PROCESS FOR PREPARATION OF 1-[9H-CARBAZOL-4-YLOXY]-3-[{2-(2-(METHOXY)PHENOXY)-ETHYL}-AMINO]-PROPAN-2-OL | SUN PHARMACEUTICAL INDUSTRIES LTD (IN) | 2006-11-30 | — | — | US | claimed |
| WO-2005113502-A1 | PROCESS FOR THE PREPARATION OF CARVEDILOL | CIPLA LIMITED (IN) | 2005-12-01 | — | — | WO | claimed |
| WO-2004113296-A1 | A PROCESS FOR PREPARATION OF 1-[9H-CARBAZOL-4-YLOXY]- 3-[{2-(2-(-(METHOXY)PHENOXY)-ETHYL}-AMINO]-PROPAN-2-OL | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2004-12-29 | — | — | WO | claimed |
| EP-0231444-A2 | Optically active isomers and racemate of 1-(benztriazol-4-yloxy)-3-[2-(2-methoxyphenoxy)-ethylamino]-2-propanol, process for their preparation as well as their use as medicaments | Roche Diagnostics GmbH (DE) | 1987-08-12 | — | — | EP | claimed |
| CN-102285910-B | Method for preparing (S) -carvedilol | NANJING UNIVERSITY OF TECHNOLOGY | 2013-06-19 | — | — | CN | disclosed |
| CN-102285910-A | Method for preparing (S) -carvedilol | — | 2011-12-21 | — | — | CN | disclosed |
| US-7875730-B2 | Reacting 4-(oxiran-2-ylmethoxy)-9H-carbazole with 2-(2-methoxyphenoxy)ethylamine to make(+-) 1-(9H-carbazol-4-yloxy))-3-[2-(2-methoxyphenoxy)ethyl]amino-2-propanol; nonselective beta -adrenergic activity | CADILA HEALTHCARE LTD. (IN) | 2011-01-25 | — | — | US | disclosed |
| US-7875730-B2 | Reacting 4-(oxiran-2-ylmethoxy)-9H-carbazole with 2-(2-methoxyphenoxy)ethylamine to make(+-) 1-(9H-carbazol-4-yloxy))-3-[2-(2-methoxyphenoxy)ethyl]amino-2-propanol; nonselective beta -adrenergic activity | CADILA HEALTHCARE LTD. (IN) | 2011-01-25 | — | — | US | disclosed |
| US-7858811-B2 | Process for the preparation of indoles | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| EP-0231444-A2 | Optically active isomers and racemate of 1-(benztriazol-4-yloxy)-3-[2-(2-methoxyphenoxy)-ethylamino]-2-propanol, process for their preparation as well as their use as medicaments | Roche Diagnostics GmbH (DE) | 1987-08-12 | — | — | EP | disclosed |
| US-4642309-A | CARDIOTONIC AGENTS | BOEHRINGER MANNHEIM GMBH (DE) | 1987-02-10 | — | — | US | disclosed |
| US-4503067-A | HYPOTENSIVE, ANGINA PECTORIS | BOEHRINGER MANNHEIM GMBH (DE) | 1985-03-05 | — | — | US | disclosed |
| EP-0064487-A1 | New substituted 3-(parasubstituted)phenoxy-1-alkylamino-propanol-2-s, as well as process for their preparation, pharmaceutical preparations containing same, and method for treating cardiac failure | Aktiebolaget Hässle (SE) | 1982-11-10 | — | — | EP | disclosed |
| EP-0004920-B1 | DERIVATIVES OF CARBAZOLYL-4-OXYPROPANOLAMINE, METHODS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1981-08-05 | — | — | EP | disclosed |
| EP-0004920-A1 | Derivatives of carbazolyl-4-oxypropanolamine, methods for their preparation and medicines containing them | Roche Diagnostics GmbH (DE) | 1979-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270858-A1 | A PROCESS FOR PREPARATION OF 1-[9H-CARBAZOL-4-YLOXY]-3-[{2-(2-(METHOXY)PHENOXY)-ETHYL}-AMINO]-PROPAN-2-OL | OXER1, CYP3A43, CYP1B1 | HTR1A 437/4885ADRA1D 113/4885ADRA1A 169/4885 |
| US-20080234492-A1 | Process for the Preparation of Carvedilol | ADRB2, ADRB3, ADRB1 | HTR1A 1503/4885ADRA1D 17/4885ADRA1A 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.